Author: Ophthalmology

Gonioscopy-Assisted Transluminal Trabeculotomy, A Novel Ab Interno Trabeculotomy: Technique Report and Preliminary Results – Corrected Proof

Purpose: To introduce a novel, minimally invasive, ab interno approach to a circumferential 360-degree trabeculotomy and to report the preliminary results.Design: Retrospective, noncomparative cases series.Participants: Eighty-five eyes of 85 consecutive patients who sought treatment at Glaucoma Associates of Texas with uncontrolled open-angle glaucoma and underwent gonioscopy-assisted transluminal trabeculotomy (GATT) for whom there was at least 6 months of follow-up data.Methods: Retrospective chart review of patients who underwent GATT by 4 of the authors (D.S.G., D.G.G., O.S., R.L.F.) between October 2011 and October 2012. The surgery was performed in adults with various open-angle glaucomas.Main Outcome Measures: Intraocular pressure (IOP), glaucoma medications, (Read more...)

Clinical Measurement of the Angle of Ocular Movements in the Nine Cardinal Positions of Gaze – Corrected Proof

Purpose: To measure the maximum angle of ocular versions using photographs of the 9 cardinal positions and a modified limbus test.Design: An evaluation of diagnostic technology; a prospective observational study.Participants: We enrolled 104 healthy subjects, 20 to 40 years of age.Methods: Photographs were obtained in the 9 cardinal positions of gaze and the images were processed using Photoshop. The images were analyzed using the Image J program to measure the angle of version. The maximum angle of the 9 cardinal positions was quantified using a modified limbus test.Main Outcome Measures: We measured the maximum angle of ocular versions in the (Read more...)

Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration – Corrected Proof

Purpose: We sought to determine the most cost-effective treatment for patients with newly diagnosed neovascular macular degeneration: monthly or as-needed bevacizumab injections, or monthly or as-needed ranibizumab injections.Design: Cost-effectiveness analysis.Participants: Hypothetical cohort of 80-year-old patients with newly diagnosed neovascular macular degeneration.Methods: Using a mathematical model with a 20-year time horizon, we compared the incremental cost-effectiveness of treating a hypothetical cohort of 80-year-old patients with newly diagnosed neovascular macular degeneration using monthly bevacizumab, as-needed bevacizumab, monthly ranibizumab, or as-needed ranibizumab. Data came from the Comparison of Age-related macular degeneration Treatment Trial (CATT), the Medicare Fee Schedule, and the medical literature.Main Outcome (Read more...)

Assessment of Iris Surface Features and Their Relationship with Iris Thickness in Asian Eyes – Corrected Proof

Purpose: To assess iris surface features in Asian eyes and examine their associations with iris thickness measured by anterior segment optical coherence tomography (AS OCT).Design: Cross-sectional study.Participants: We recruited 250 subjects from the Singapore Malay Eye Study.Methods: We obtained standardized slit-lamp photographs and developed a grading system assessing iris crypts (by number and size), furrows (by number and circumferential extent), and color (higher grade denoting darker iris). Vertical and horizontal cross-sections of the anterior chamber were imaged using AS OCT. Intragrader and intergrader agreements in the grading of iris surface were assessed by weighted κ (κw) statistic. Associations of the (Read more...)

Proton Therapy for Uveal Melanoma in 43 Juvenile Patients: Long-Term Results – Corrected Proof

Purpose: To examine the metastatic and survival rates, eye retention probability, and the visual outcomes of juvenile patients after proton beam radiotherapy (PBRT) for uveal melanoma (UM).Design: Retrospective case-factor matched control study.Participants and Controls: Forty-three patients younger than 21 years treated with PBRT for UM were compared with 129 matched adult control patients.Methods: Information on patient demographics and clinical characteristics were recorded before and after treatment from patients’ files. The control group was composed of adult patients (>21 years) matched for tumor size (largest tumor diameter, ±2 mm; height, ±2 mm) and anterior margin location (iris, ciliary body, pre-equatorial or (Read more...)

Intraocular Pressure in Eyes Receiving Monthly Ranibizumab in 2 Pivotal Age-Related Macular Degeneration Clinical Trials – Corrected Proof

Purpose: To characterize preinjection intraocular pressure (IOP) in eyes receiving monthly ranibizumab versus sham or verteporfin photodynamic therapy (PDT) for age-related macular degeneration (AMD).Design: Post hoc analysis of IOP data from 2 phase 3 clinical trials, the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) and the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) trial.Participants: All safety-evaluable patients who received 1 or more injections of sham or PDT or of ranibizumab and had 1 or more postbaseline IOP measurements recorded for the study eye.Methods: Preinjection IOP measurements (Read more...)

A Randomized, Controlled Trial of Corneal Collagen Cross-Linking in Progressive Keratoconus: Three-Year Results – Corrected Proof

Purpose: To report the refractive, topographic, and clinical outcomes 3 years after corneal collagen cross-linking (CXL) in eyes with progressive keratoconus.Design: Prospective, randomized controlled trial.Participants: One hundred eyes with progressive keratoconus were randomized into the CXL treatment or control groups.Methods: Cross-linking was performed by instilling riboflavin 0.1% solution containing 20% dextran for 15 minutes before and during the 30 minutes of ultraviolet A irradiation (3 mW/cm2). Follow-up examinations were arranged at 3, 6, 12, 24, and 36 months.Main Outcome Measures: The primary outcome measure was the maximum simulated keratometry value (Kmax). Other outcome measures were uncorrected visual acuity (UCVA; measured (Read more...)

期刊一览

Shah (p. 352) 等人分析了肺癌葡萄膜转移患者的临床特征、治疗及预后。 他们发现,44%葡萄膜转移癌患者在转移灶发现时并未诊断出肺癌。另外,他们还发现,尽管现阶段的眼部治疗方案可以尽…

This Issue At A Glance

Shah et al (p. 352) assessed the clinical features, treatment, and prognosis of patients with uveal metastasis from lung cancer. They found that 44% of patients with uveal metastasis had not been diagnosed with lung cancer at the time the metastasis w…

A Simple Vista en Este Número

Shah y otros (p. 352) evaluaron las características, el tratamiento y el pronóstico clínico de pacientes con metástasis uveal por cáncer de pulmón. Encontraron que 44% de los pacientes con metástasis uveal no habían sido diagnosticados con cán…

Corrigendum

With apologies from the authors of “Preterm Birth and Later Retinal Detachment: A Population-Based Cohort Study of More than 3 Million Children and Young Adults” (Ophthalmology 2013;120:2278-2285), the 6th paragraph on the 2nd column (p. 2280) shou…

Polymorphisms in Vascular Endothelial Growth Factor Receptor 2 Are Associated with Better Response Rates to Ranibizumab Treatment in Age-related Macular Degeneration – Corrected Proof

Purpose: Intravitreal anti–vascular endothelial growth factor (VEGF) injections are currently the standard treatment for neovascular age-related macular degeneration (AMD), but a broad range of response rates has been observed. We evaluated the assoc…